In Brazil, malaria still remains a clinically important febrile syndrome for local populations
and travelers, occurring mostly in the Amazon Basin. This review aims to report the main …

Background Plasmodium vivax resistance to chloroquine (CQ) has been reported
worldwide, although the World Health Organization clinical drug efficacy studies protocol …

Background Chloroquine (CQ), a cost effective antimalarial drug with a relatively good safety
profile and therapeutic index, is no longer used by itself to treat patients with Plasmodium …

Background Plasmodium vivax accounts for about 40% of all malaria infection in Ethiopia.
Chloroquine (CQ) is the first line treatment for confirmed P. vivax malaria in the country. The …

The aim of this study was to determine how different types of P. vivax affect clinical
symptoms and parasitaemia clearance. Blood was collected from individuals from Pará …

Background Chloroquine is the first-line treatment for Plasmodium vivax malaria in most
endemic countries, but resistance is increasing. Monitoring of antimalarial efficacy is …

Objective To assess the efficacy of chloroquine in the treatment of Plasmodium vivax malaria
in in Dawei District, southern Myanmar. Methods Enrolled patients at Sonsinphya clinic> 6 …

To the Editor: Plasmodium vivax is the protozoan that causes the second most common form
of malaria. Some resistant strains to chloroquine (CQ) occur in a few places in Asia and the …

Background There are increasing reports of severe clinical cases exclusively associated
with Plasmodium vivax infections. Notably, this severity has been recently suggested to be …

Chloroquine-resistant Plasmodium vivax has been the subject of numerous case reports
and prospective studies from Oceania and Asia. In contrast, only case reports exist from the …